Skip to main content
Clinical Trials/EUCTR2021-003588-85-BE
EUCTR2021-003588-85-BE
Active, not recruiting
Phase 1

Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders-How to conciliate plasma concentrations, clinical response and genetic factors ?

CLouvain0 sites100 target enrollmentOctober 12, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Schizophrenia, schizoaffective disorders,psychosis not otherwise specified, and dellusional disorders
Sponsor
CLouvain
Enrollment
100
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 12, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
CLouvain

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria are : (1\) diagnosis of schizophrenia\-spectrum disorders7 (DSM\-V 295\.xx,
  • 298\.9 and 297\.1 ; or ICD\-10 F20\.xx, F25\.xx, F29 and F22; or ICD\-11 6A20, 6A21, 6A2Z and
  • 6A24\), (2\) hospitalized in a psychiatric unit of each center for an acute episode of psychosis, (3\) aged between 18 and 65 years old at admission; and (4\) taking a monotherapy8 of
  • aripiprazole, olanzapine or risperidone at admission or any time during their hospital stay for
  • their psychotic symptoms until steady state of their antipsychotic is reached.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 100
  • F.1\.3 Elderly (\>\=65 years) no

Exclusion Criteria

  • Exclusion criteria are: (1\) comorbid disorder of intellectual development (i.e. intellectual
  • disability also commonly called mental retardation, DSM\-V criteria 317\.xx and 318\.xx), (2\)
  • comorbid serious uncontrolled illness or dementia9; (3\) comorbid substance use disorder (DSMV
  • 305\.20, 304\.30, 305\.90, 304\.60, 305\.30, 304\.50, 305\.50, 304\.00, 305\.40, 304\.10, 305\.70,
  • 305\.60, 304\.40, 304\.20\) in case of consumption during the hospital stay10 (4\) comorbid alcohol
  • use disorder (DSM\-V 305\.00 and 303\.90\); (5\) women with a current pregnancy11 ; (6\)
  • hospitalization for a social purpose (e.g. nursing home time out) or planned hospitalization
  • without exacerbation ; (7\) patients not speaking French, English or Dutch to a standard
  • necessary to receive the assessment scales; (8\) patients with an hepatic fibrosis Child Pugh C
  • and severe renal failure (i.e. Clcr \<30 mL/min) identified through chart review.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Efficacy of treatment with antipsychotics in patients with psychotic disorder. The value of amino acid profile and neurotrophic proteins.psychosisschizophrenia10039628
NL-OMON31735GGZ Groep Noord en Midden-Limburg100
Withdrawn
Not Applicable
Treating acute psychotic symptoms in an inpatient service using Acceptance and Commitment TherapyAcute psychotic symptomsMental Health - SchizophreniaMental Health - Psychosis and personality disorders
ACTRN12609000603213St Vincent's Hospital, Mental Health60
Active, not recruiting
Not Applicable
Supporting psychiatric treatment and therapy of unipolar depression through the use and application of health enabling technologiesF32.1F32.2F33.1F33.2Moderate depressive episodeSevere depressive episode without psychotic symptomsRecurrent depressive disorder, current episode moderateRecurrent depressive disorder, current episode severe without psychotic symptoms
DRKS00022922Peter L. Reichertz Institut für Medizinische Informatikder TU Braunschweig und der Medizinischen Hochschule Hannover (PLRI)10
Completed
Not Applicable
Atypical antipsychotics for continuation and maintenance treatment after an acute manic episodeBipolar disorderMental and Behavioural Disorders
ISRCTN76555175niversity of British Columbia (Canada)540
Recruiting
Not Applicable
Pharmaceutical Care of psychiatric patients in hospitalF00-F99Mental and behavioural disorders
DRKS00006358Professur für Molekulare und Klinische Pharmazie, Friedrich-Alexander-Universität Erlangen-Nürnberg184